Physician profile
Erwin M Manalo
NPI 1982697876
$3,715.62
in general payments reported to CMS, 2019-2025
40 companies · $412 in 2025
The $412 reported for 2025 was more than what 77% of Brain Injury Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $784 · 2021: $873 · 2022: $398 · 2023: $392 · 2024: $351 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $411.43 | 2019-2025 | Dysport |
| Avanir Pharmaceuticals, INC. | $403.77 | 2019-2022 | |
| Abbvie INC. | $381.68 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $306.78 | 2020-2022 | |
| Amgen INC. | $250.03 | 2019-2023 | Prolia, Evenity |
| Radius Health, INC. | $246.64 | 2019-2025 | Tymlos |
| Allergan, INC. | $232.81 | 2019-2022 | |
| Pfizer INC. | $146.05 | 2019-2025 | |
| Pacira Therapeutics, INC. | $130.28 | 2019-2021 | |
| Tersera Therapeutics LLC | $122.59 | 2019-2025 | Prialt |
| Astrazeneca Pharmaceuticals Lp | $108.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $98.69 | 2023-2025 | Nuedexta |
| Collegium Pharmaceutical, INC. | $79.94 | 2020-2024 | Belbuca, Xtampza |
| Saol Therapeutics INC. | $61.51 | 2019-2021 | |
| Merz North America, INC. | $57.38 | 2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Manalo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.